Breast cancer
Not yet recruitingDiscontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab
Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab
- Disease:Breast cancer
- Substances:PertuzumabTrastuzumab
Spain- Participants:18–64 years · 65+ years
- Substances:Pertuzumab
- Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana









